Official Title
Impact of the COVID-19 Pandemic on Changes in Therapeutic Strategies in Gynecological Oncology
Brief Summary

The current infection with the Coronavirus SARS-CoV-2 (COVID-19) is an exceptional health situation which requires an adaptation of our management practices in gynecological oncology. Data from the literature suggest that infection with Coronavirus is serious in subjects with cancer with a risk of severe form 5 times higher than that of the population without cancer and a risk of death multiplied by 8. In addition, the risk of infection would be 3 times greater in case of cancer. Faced with the COVID-19 epidemic, the investigator must organize themselves to ensure continuity in the treatment of patients with gynecological cancer but also adapt our practices in the management (CPR, teleconsultation, adaptation of treatment or even postponement of treatment). The objective of the High Council of Public Health is to be able to ensure adequate oncological care avoiding any potential loss of chance concerning the care of cancer: people affected must, despite the pandemic, have care allowing the same level of curability (localized cancers) or the same life expectancy (advanced cancers). This must be done by limiting as much as possible the impact on the organization of the service, the organization of patient follow-up and the psychological impact that these possible modifications could have. The hypotheses of our study are that the exceptional health situation linked to this pandemic leads to a change in the care of patients with gynecological cancer associated with a psychological impact and increased anxiety of patients during their care. Despite the extent of the pandemic, very little existing data makes it possible to define recommendations with a sufficient level of evidence.

Completed
Gynecologic Cancer
Breast Neoplasm Female
Uterine Neoplasms
Ovarian Neoplasms
Uterine Cervical Neoplasms
Vulvar Neoplasms
Vaginal Neoplasms

Other: modification of the planned therapeutic management

to evaluate the changes in therapeutic management, during the COVID-19 pandemic, of patients suffering from gynecological cancers

Eligibility Criteria

Inclusion Criteria:

- women over 18

- gynecological cancer (breast cancer, uterus, ovary, cervix, vagina or vulva cancer)

- therapeutic management planned during quarantine

- person having expressed his non-opposition

Inclusion Criteria of control group :

- women over 18

- gynecological cancer (breast, uterus, ovary, cervix, vagina or vulva cancer)

- therapeutic management planned on the end of the year 2019

- person having expressed his non-opposition

Exclusion Criteria:

- inability to understand the information given

- person deprived of liberty,

- person under guardianship.

Eligibility Gender
Female
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
France
Locations

Service de Gynécologie, HFME, Hospices Civils de Lyon
Bron, France

Service de Gynécologie, Croix-Rousse, Hospices Civils de Lyon
Lyon, France

Service Gynécologie, CHLS, Hospices Civils de Lyon
Pierre-Bénite, France

Géry LAMBLIN, Principal Investigator
Gynaecology Department, Hôpital Femme Mère Enfant Hospices Civils de Lyon

Hospices Civils de Lyon
NCT Number
Keywords
Gynecologic Cancer
Covid-19
MeSH Terms
COVID-19
Neoplasms
Breast Neoplasms
Ovarian Neoplasms
Uterine Cervical Neoplasms
Uterine Neoplasms
Vulvar Neoplasms
Vaginal Neoplasms